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ABSTRACT
Our previous study showed that administering oxaliplatin as first-line 
chemotherapy increased ERCC1 and DPD levels in liver colorectal cancers (CRCs) 
metastases. Second, whether the anti-VEGF monoclonal antibody bevacizumab alters 
tumoral VEGFA levels is unknown. We conducted this multicenter observational study 
to validate our previous findings on ERCC1 and DPD, and clarify the response of 
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INTRODUCTION
Acquired resistance to chemotherapy and 
molecular-targeted therapy of human cancers is mediated 
by molecular alterations. Thus, understanding these 
alterations is increasingly important for predicting 
whether a patient will respond to chemotherapy and for 
counteracting resistance to anticancer agents. 
The standard first-line chemotherapeutic regimen 
for metastatic colorectal cancer (CRC) is a combination 
of fluorouracil (5-FU) and folinic acid with oxaliplatin 
(i.e., FOLFOX) or irinotecan (i.e., FOLFIRI) with or 
without targeted agents.[1-3] Additionally, several 
second-line therapy regimes have been proposed for 
patients with recurring or progressive disease.[4-8] In a 
randomized phase II/III FIRIS study, IRIS (irinotecan/S-1) 
and FOLFIRI (5-FU–leucovorin/irinotecan) treatments 
yielded similar outcomes.[9, 10] Interestingly, this study 
reported a longer overall survival of patients in the IRIS 
group, previously undertaking oxaliplatin-containing 
chemotherapy, than patients in the FOLFIRI group. 
However, the reason for this remains poorly understood 
at the molecular level. To clarify the relevant molecular 
mechanisms, we previously conducted a single-center 
retrospective study of 45 CRC tissues. We found that 
administering oxaliplatin as first-line chemotherapy to 
CRC patients with liver metastases enhanced the patients’ 
expression levels of two important genes: excision repair 
cross-complementing group 1 (ERCC1, a nucleotide 
excision repair pathway gene) and dihydropyrimidine 
dehydrogenase (DPYD, a pyrimidine catabolic pathway 
gene). We thus hypothesized that IRIS regimens combined 
with the DPD inhibitory fluoropyrimidine S-1 would 
be more effective against DPD-high tumors than the 
FOLFIRI regime.[11] However, our previous study was 
limited by a relatively small number of patients sourced 
from a single institute.
Bevacizumab is an anti-vascular endothelial growth 
factor (VEGF) monoclonal antibody commonly included 
in first-line therapy of metastatic CRC.[12, 13] Once 
disease has progressed beyond first line chemotherapy, 
maintaining VEGF inhibition by bevacizumab has proven 
a clinically beneficial adjunct to standard second-line 
chemotherapy.[14-18] However, the biological rationale of 
continuing bevacizumab beyond first progression remains 
elusive. Given that circulating levels of short vascular 
endothelial growth factor A (VEGFA) isoforms and 
genetic variants of VEGFA or its receptors are promising 
biomarker candidates for bevacizumab,[19] we propose 
that investigating the VEGFA expression levels before 
and after first-line bevacizumab treatment may help to 
elucidate this rationale.    
The present multicenter observational study of 346 
CRC patients validates our previous findings that ERCC1 
and DPYD expression levels are altered by oxaliplatin-
based chemotherapy. We also evaluate the response of 
VEGFA expression levels to bevacizumab administration. 
RESULTS
Patient characteristics
Table 1 summarizes the characteristics of the 
study patients. The mean patient age at the time of 
liver dissection was 64.5 years (range 32–89 years). 
Oxaliplatin as first-line chemotherapy was administered 
to 166 patients under the following regimes: FOLFOX 
(92 patients), FOLFOX + Bevacizumab (52 patients), 
XELOX+ Bevacizumab (5 patients), XELOX (3 patients), 
and other regimens (14 patients).
Patients in the oxaliplatin-based chemotherapy 
group (chemotherapy group) were generally younger (P 
= 0.0014) and had more liver metastases (P = 0.0001) 
than patients in the non-chemotherapy group (Table 1). 
The mean number of liver metastases in the chemotherapy 
group was 3.51 (range 1–19), versus 2.14 in the non-
chemotherapy group (range 1–14) (P < 0.0001). There was 
no significant difference in sex, tumor location, or tumor 
differentiation between the two groups. 
VEGFA expression to bavacizumab administration. 346 CRC patients with liver metastases 
were enrolled at 22 Japanese institutes. Resected liver metastases were available for 175 
patients previously treated with oxaliplatin-based chemotherapy (chemotherapy group) 
and 171 receiving no previous chemotherapy (non-chemotherapy group). ERCC1, DPYD, 
and VEGFA mRNA levels were measured by real-time RT-PCR. ERCC1 mRNA expression 
was significantly higher in the chemotherapy group than in the non-chemotherapy group 
(P = 0.033), and were significantly correlated (Spearman’s correlation coefficient = 0.42; 
P < 0.0001). VEGFA expression level was higher in patients receiving bevacizumab (n = 
51) than in those who did not (n = 251) (P = 0.007). This study confirmed that first-line 
oxaliplatin-based chemotherapy increases ERCC1 and DPYD expression levels, potentially 
enhancing chemosensitivity to subsequent therapy. We also found that bevacizumab 
induces VEGFA expression in tumor cells, suggesting a biologic rationale for extending 
bevacizumab treatment beyond first progression. 
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ERCC1 and DPYD mRNA expression levels with 
and without a prior oxaliplatin regimen
As shown in Figure 2, ERCC1 mRNA expression 
was significantly higher in the chemotherapy group 
(mean 7.11; median 7.12) than in the non-chemotherapy 
group (mean 6.94; median 6.88) (P = 0.033). DPYD 
mRNA expression was similarly elevated in the 
chemotherapy group (mean 5.32; median 5.17) relative 
to the non-chemotherapy group (mean 5.04; median 
5.17) (P = 0.023). In the chemotherapy group, ERCC1 
or DPYD mRNA levels were unassociated with the 
number of chemotherapeutic cycles and with type of 
chemotherapeutic regimen (data not shown). However, 
expression levels of ERCC1 and DPYD were significantly 
correlated (Spearman’s correlation coefficient = 0.42; P 
< 0.0001) (Figure 3), consistent with the findings of our 
previous single-center study.[11]
Given that chemotherapy history was significantly 
related to patient age and number of liver metastasis 
(Table 1), we correlated mRNA levels of ERCC1 and 
DPYD with both parameters. Age was not associated with 
ERCC1 (Spearman’s correlation coefficient = -0.02; P 
= 0.51) or DPYD mRNA level (Spearman’s correlation 
coefficient = −0.04; P = 0.71). Similarly, no relationship 
was found between number of liver metastasis and ERCC1 
or DPYD mRNA levels (P = 0.69 and P = 0.76 for ERCC1 
and DPYD, respectively).
We also examined whether a prior oxaliplatin 
regimen altered the mRNA expression of DNA 
topoisomerase I (TOP1), a recognized predictive 
biomarker of irinotecan therapy. No significant difference 
in TOP1 mRNA level was found between the groups 
receiving and not receiving oxaliplatin (Figure 2).
Immunohistochemical results
The RT–PCR analysis revealed higher expression of 
ERCC1 and DPYD mRNA in oxaliplatin-treated patients 
than in non-treated patients. The protein expression levels 
of these genes were determined by immunohistochemical 
examination. Tumor cells contained appreciable quantities 
Table 1: Patients characteristics 
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Figure 1: Flowchart of the present study.
Figure 2: Comparison of expression levels of ERCC1, DPYD, and TOP1 genes in tumor cells with and without 
oxaliplatin-based chemotherapy before hepatectomy. 
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of ERCC1 protein, especially in the nucleus, whereas 
both tumor and stromal cells expressed DPD protein 
(Supplemental figure 1). One of the investigators, blinded 
to all other participant data, classified nuclear ERCC1 and 
DPD expression as absent, weak, moderate, or strong. 
Tumors with weak to strong expression were defined 
as “positive,” and tumors not expressing these proteins 
were defined as “negative.” Among 340 colorectal liver 
metastases, 181 (55%) and 131 (39%) tumors tested 
positive for ERCC1 and DPD, respectively. Importantly, 
ERCC1 and DPD positivity was significantly associated 
with mRNA expression levels for each gene (P=0.0042 
for DPD, P<0.001 for ERCC1). Positive DPD was 
significantly associated with prior oxaliplatin-based 
chemotherapy (p = 0.027; see Supplemental Table 2), 
consistent with the RT–PCR results. Conversely, ERCC1 
expression was unrelated to prior oxaliplatin-based 
chemotherapy (p = 0.44; Supplemental Table 2).  
VEGFA expression level and bevacizumab 
To test the effect of bevacizumab on VEGFA mRNA 
expression, we evaluated the mRNA expression level 
of VEGFA in the presence and absence of bevacizumab 
therapy. In this study, 63 patients had received a prior 
bevacizumab-including regimen, while 277 patients had 
not received this therapy. Among the non-bevacizumab 
group, 172 and 105 patients had received a prior 
oxaliplatin-including regimen and no chemotherapy, 
respectively. Results of tumoral VEGFA mRNA were 
available in 301 patients. Importantly, VEGFA mRNA 
expression level was higher in patients receiving 
bevacizumab (n = 51; mean = 3.18, median = 3.12) than 
in their non-bevacizumab counterparts (n = 251; mean = 
2.81, median = 2.89) (p = 0.007) (Figure 4A). Additionally, 
we found that whereas VEGFA mRNA expression levels 
were unaffected by oxaliplatin-based chemotherapy, they 
were significantly altered by bevacizumab (P = 0.014) 
(Figure 4B). The bevacizumab-including regimen did 
not influence the expression levels of ERCC1, DPYD, or 
TOP1 (P > 0.10).  
DISCUSSION
Our multicenter study of 346 CRC patients revealed 
significantly higher ERCC1 and DPYD expression in 
patients receiving oxaliplatin as a first-line chemotherapy 
than in patients receiving no chemotherapy. Given that 
IRIS (irinotecan/S-1) regimens based on the DPD inhibitor 
fluoropyrimidine may be more effective against DPD-
Figure 3: Relationship between ERCC1 and DPYD expression levels.
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high tumors than FOLFIRI, this finding is consistent 
with a recent clinical study, which suggested that patients 
previously treated with oxaliplatin-based chemotherapy 
better responded to IRIS than to FOLFIRI.[9, 10] Second, 
we found that administering bevacizumab to patients 
raised their VEGFA expression levels, supporting that 
bevacizumab encourages VEGFA mRNA expression 
from tumor cells via feedback or alternative unknown 
mechanisms. This phenomenon provides a possible 
biologic rationale for continuing bevacizumab after first 
progression.  
Molecular responses to chemotherapy and 
molecular-targeted therapy have been implicated in 
acquired resistance to these therapies. Thus, by better 
understanding these molecular alterations, we may select 
a more effectual second-line regimen. To our knowledge, 
we present the first demonstration of a basic rationale 
for second-line therapy following failure of oxaliplatin-
based first-line therapy in CRC patients. Additionally, 
we hypothesized the biologic rationale for continuing 
bevacizumab treatment after first progression. In this 
context, the clinical implications of our study could be 
considerable.  
Although a previous analysis found that IRIS 
was superior to FOLFIRI in patients previously treated 
with oxaliplatin-based chemotherapy,[9] the molecular 
mechanisms underlying this finding were not clarified. In 
our previous in-silico study of cell-line panel data retrieved 
from the National Cancer Institute 60 (NCI60), oxaliplatin 
and 5-FU sensitivities were significantly correlated, and 
cells resistant to oxaliplatin showed significantly higher 
ERCC1 and DPD expression than sensitive cells.[11] 
Clinical samples also confirmed that the cancer cells of 
FOLFOX-treated patients expressed significantly more 
ERCC1 and DPD than cells of non-treated patients. 
Based on these findings, we propose the following 
hypothesis (Figure 5A). Following first-line oxaliplatin-
based treatment, oxaliplatin-sensitive tumor cells (with 
low ERCC1 levels; colored gray in Figure 5A) are killed, 
whereas a small fraction of relatively oxaliplatin-resistant 
cells (with high ERCC1 levels; colored red in Figure 
5A) survive. The NCI60 cell-line data reveal ERCC1 
and DPYD gene expressions as confounding factors; 
therefore, surviving cells will express high levels of both 
ERCC1 and DPYD. As the IRIS regimen contains the 
DPD inhibitory fluoropyrimidine S-1,[20] it will more 
effectively target DPD-high tumors than FOLFIRI (based 
on fluoropyrimidine, which does not inhibit DPD). This 
hypothesis was supported in the current study of more 
than 300 CRC samples retrieved from multiple centers. 
Of course, these findings must be consolidated by 
further studies. We also need to elucidate the molecular 
mechanisms underlying the confounding effects of ERCC1 
and DPYD gene expression in cancer cells. 
Continuing VEGF inhibition by bevacizumab 
treatment beyond disease progression is widely accepted 
as beneficial for patients with metastatic CRC. [14-
18] According to the “normalization” hypothesis, 
bevacizumab instigates a redistribution of tumor blood 
flow, increasing the delivery of chemotherapy to the tumor.
Figure 4: Comparison of VEGFA expression levels in tumor cells with and without bevacizumab treatment before 
hepatectomy.
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[21, 22] Another possible mechanism is treatment-related 
changes in VEGFA, although attempts to predict the effect 
of bevacizumab on tumor or plasma VEGFA levels have 
been largely inconsistent. Several clinical studies have 
demonstrated that bevacizumab delivery elevates levels 
of circulating VEGFA.[19, 23, 24] Nonetheless, to our 
knowledge, the effect of bevacizumab on tumoral VEGFA 
levels has not been previously reported. CRC cells exposed 
to bevacizumab increase their VEGFA gene expression, 
with consequent increases in tumor cell migration and 
invasion, and metastatic potential in vivo.[25] Collectively, 
our findings suggest that bevacizumab encourages VEGFA 
mRNA expression in tumor cells via an unknown feedback 
mechanism. Therefore, bevacizumab is a clinical necessity 
even after first progression (Figure 5B). 
There are advantages in accessing the databases of 
multiple centers. The importance of large-scale studies 
cannot be overemphasized, because small studies yielding 
significant results are much more likely to be published 
than those yielding null results, leading to publication 
Figure 5: A. Proposed molecular mechanism underlying the superiority of IRIS treatment in prior oxaliplatin-treated patients. Oxaliplatin-
resistant tumor cells may be sensitized to IRIS therapy by their high ERCC1 and DPD levels. B. Proposed molecular mechanism rationalizing 
continued bevacizumab treatment after first progression. Bevacizumab may encourage VEGFA mRNA expression from tumor cells via an 
unknown feedback mechanism.
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bias. The 346 participants in the present study were 
treated at 22 hospitals throughout Japan. Thus, this 
sample better represents the Japanese CRC population 
than samples collected from a few academic hospitals. The 
limitations of a multiple database study are that resected 
specimen-handling procedures (such as taking samples 
and preparing formalin-fixed paraffin-embedded tissues) 
subtly differ among medical centers. This may explain 
our unexpected result that ERCC1 immunostaining is 
independent of prior oxaliplatin-based chemotherapy. 
Another limitation may be the lack of tumor specimens 
which are obtained before chemotherapeutic treatment. 
The current retrospective study could not examine the 
relationship between pre-treatment status of ERCC1 and 
DPYD expression and therapeutic response. In addition, 
we could not set the cut-offs for these molecular markers 
toward the future practical application in the clinical 
setting. We acknowledge that a well-planned prospective 
study is necessary to overcome these limitations. 
In summary, this multicenter study revealed that 
ERCC1 and DPYD expression levels are increased by 
first-line oxaliplatin-based chemotherapy, with possible 
impacts on chemosensitivity to subsequent therapy. 
Second, we found that bevacizumab administration 
boosts VEGFA expression levels in the tumors of receiving 
patients, providing a possible biologic rationale for 
continuing bevacizumab treatment after first progression. 
MATERIALS AND METHODS
Study subjects
This retrospective study included 346 CRC 
patients who underwent hepatectomy for liver metastasis 
between April 2005 and October 2013 at 22 institutions 
in Japan. All tumors were histologically diagnosed as 
adenocarcinomas of the colon or rectum. As the aim 
of this study was to compare the expression levels of 
ERCC1, DPYD and VEGFA between patients receiving 
oxaliplatin-based chemotherapy and patients receiving 
no chemotherapy, we enrolled both types of patients 
equally. As a result, 171 patients had undergone no 
chemotherapy prior to hepatectomy, and 175 patients had 
received oxaliplatin-based chemotherapy [5-fluorouracil, 
leucovorin, and oxaliplatin (FOLFOX) (92 cases), 
FOLFOX + Bevacizumab (58 cases), capecitabine and 
oxaliplatin (XELOX) (5 cases), XELOX + Bevacizumab 
(5 cases), other treatments (15 cases)] prior to 
hepatectomy. On average, the chemotherapy group had 
received 8 courses (cycles) of treatment (range 2–34 
courses). We initially subjected 346 cancer specimens to 
molecular analyses (i.e., immunohistochemical staining 
and quantitative reverse transcription polymerase chain 
reaction (RT-PCR), and retrieved valid results from 336 
(97%) of the specimens. Thus, 336 colorectal tumors (166 
from the oxaliplatin-based chemotherapy group and 170 
from the no-chemotherapy group) were finally included 
in this study (Figure 1). The study protocol was approved 
by the independent ethics committee of each participating 
institution. 
Quantitative RT-PCR 
The protocols of RNA isolation and cDNA synthesis 
are shown in Supplemental data 1. Gene expression 
levels of ERCC1, DPYD, topoisomerase-1 (TOP1) and 
VEGFA were determined by TaqMan real-time PCR (Life 
Technologies, Foster City, CA) as previously described.
[26, 27] The endogenous reference gene was β-Actin 
(ACTB). All genes from all samples were run in triplicate. 
The smallest detectable quantity of amplified cDNA 
defines the cycle threshold (Ct) value, which is inversely 
proportional to the cDNA content. Universal Mix RNAs 
(Stratagene, La Jolla, CA) were used as control calibrators 
on each plate. The primer sequences for ERCC1, DPYD, 
TOP1, VEGFA and ACTB were as previously described.
[27, 28] The adopted primers and probes are listed in 
Supplemental Table 1.
The PCR reaction mixture comprised 1,200 nmol/L 
of each primer, 200 nmol/L probe, 0.4 units of AmpliTaq 
Gold Polymerase, 200 nmol/L each of dATP, dCTP, 
dGTP, dTTP, 3.5 mmol/L MgCl2, and 1× Taqman buffer 
A containing a reference dye. Reagents (all purchased 
from Life technologies, Foster City, CA) were combined 
in a final volume of 20 μL. Cycling conditions were 50°C 
for 2 minutes and 95°C for 10 minutes, followed by 46 
15-second cycles at 95°C and 60°C for 1 minute. The 
threshold cycle (Ct) was the fractional cycle number at 
which the fluorescence generated by the probe cleavage 
exceeded a fixed level above baseline. The relative amount 
of tissue target mRNA, standardized against the amount 
of ACTB mRNA, was expressed as −ΔCt = − (Ct(target 
gene-1) − Ct(β-actin)). The number ratio of target mRNA 
copies to ACTB mRNA copies was then calculated as 2−
ΔCt × K, where K is a constant.[29] To prevent significant 
contamination by genomic DNA, we amplified non-
reverse-transcribed RNA only.
Immunohistochemical staining
In preparation for ERCC1 and DPD analyses, the 
slides were incubated overnight at 4°C with primary 
anti-ERCC1 monoclonal antibody (Clone D-10; Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA) and primary 
anti-DPD monoclonal antibody (Clone OF-303, Taiho 
Pharmaceutical Co., Ltd, Tokyo, Japan), respectively. Both 
antibodies were diluted by a factor of 100. The secondary 
antibody was a ready-to-use anti-mouse EnVision-
Peroxidase system (Dako Japan Inc., Tokyo, Japan). 
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The remaining procedure was performed using a Dako 
EnVision+ System (Dako Japan Inc). The chromogenic 
detection substrate was DAB (3,30-diaminobenzidine). 
The stained slides were counterstained with hematoxylin 
and bluing reagent. 
Statistical methods
Categorical data were analyzed by the w2 test. Inter-
group differences were evaluated by Student’s t-test or 
the Wilcoxon test. Results were considered statistically 
significant at the P < 0.05 level. All statistical analyses 
were performed by JMP version 8.01 software (SAS 
Institute Inc., Cary, NC).
ACKNOWLEDGEMENTS
Our study was supported by unrestricted technical 
assistance from Taiho Pharmaceutical Co., Ltd, Japan. 
We thank Kazuto Harada, Keisuke Kosumi, and Keisuke 
Miyake for their technical support. We also thank Takashi 
Kobunai for his helpful advice. 
CONFLICTS OF INTEREST
No conflict of interest exists.
REFERENCES
1. O’Neil BH and Goldberg RM. Innovations in chemotherapy 
for metastatic colorectal cancer: an update of recent clinical 
trials. The oncologist. 2008; 13:1074-1083.
2. Benson AB, 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen 
YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, 
Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, 
Messersmith W, et al. Colon cancer, version 3.2014. Journal 
of the National Comprehensive Cancer Network : JNCCN. 
2014; 12:1028-1059.
3. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, 
Glimelius B, Haustermans K, Nordlinger B, van de Velde 
CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, 
Arnold D, Ciardiello F, Hoff P, Kerr D, et al. ESMO 
Consensus Guidelines for management of patients with 
colon and rectal cancer. a personalized approach to clinical 
decision making. Annals of oncology : official journal of 
the European Society for Medical Oncology / ESMO. 2012; 
23:2479-2516.
4. Bendell JC, Nemunaitis J, Vukelja SJ, Hagenstad C, 
Campos LT, Hermann RC, Sportelli P, Gardner L and 
Richards DA. Randomized placebo-controlled phase II 
trial of perifosine plus capecitabine as second- or third-line 
therapy in patients with metastatic colorectal cancer. Journal 
of clinical oncology : official journal of the American 
Society of Clinical Oncology. 2011; 29:4394-4400.
5. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux 
M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, 
Strickland AH, Wilson G, Ciuleanu TE, Roman L, 
Van Cutsem E, Tzekova V, et al. Randomized phase III 
study of panitumumab with fluorouracil, leucovorin, and 
irinotecan (FOLFIRI) compared with FOLFIRI alone as 
second-line treatment in patients with metastatic colorectal 
cancer. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2010; 28:4706-
4713.
6. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, 
Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland 
AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, 
Tian Y, et al. Final results from a randomized phase 3 study 
of FOLFIRI {+/-} panitumumab for second-line treatment 
of metastatic colorectal cancer. Annals of oncology : official 
journal of the European Society for Medical Oncology / 
ESMO. 2014; 25:107-116.
7. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone 
A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, 
Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, 
Sargent DJ, et al. Regorafenib monotherapy for previously 
treated metastatic colorectal cancer (CORRECT): an 
international, multicentre, randomised, placebo-controlled, 
phase 3 trial. Lancet. 2013; 381:303-312.
8. Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu 
Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, 
Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T and 
Ohtsu A. TAS-102 monotherapy for pretreated metastatic 
colorectal cancer: a double-blind, randomised, placebo-
controlled phase 2 trial. The lancet oncology. 2012; 13:993-
1001.
9. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba 
H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, 
Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu 
Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil 
and folinic acid plus irinotecan (FOLFIRI) as second-
line chemotherapy for metastatic colorectal cancer: a 
randomised phase 2/3 non-inferiority study (FIRIS study). 
The lancet oncology. 2010; 11:853-860.
10. Yasui H, Muro K, Shimada Y, Tsuji A, Sameshima S, Baba 
H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, 
Esaki T, Tokunaga S, Kuwano H, Boku N, Komatsu Y, et 
al. A phase 3 non-inferiority study of 5-FU/l-leucovorin/
irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as 
second-line chemotherapy for metastatic colorectal cancer: 
updated results of the FIRIS study. Journal of cancer 
research and clinical oncology. 2015; 41: 153-60.
11. Baba H, Watanabe M, Okabe H, Miyamoto Y, Sakamoto 
Y, Baba Y, Iwatsuki M, Chikamoto A and Beppu T. 
Upregulation of ERCC1 and DPYD expressions after 
oxaliplatin-based first-line chemotherapy for metastatic 
colorectal cancer. British journal of cancer. 2012; 107:1950-
1955.
12. Harris M. Monoclonal antibodies as therapeutic agents for 
Oncotarget34013www.impactjournals.com/oncotarget
cancer. The lancet oncology. 2004; 5:292-302.
13. Hicklin DJ and Ellis LM. Role of the vascular endothelial 
growth factor pathway in tumor growth and angiogenesis. 
Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2005; 23:1011-
1027.
14. Kubicka S, Greil R, Andre T, Bennouna J, Sastre J, Van 
Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Muller 
T, Makrutzki M, Arnold D, Ml18147 study investigators 
including Aio GFUGTBG and groups A. Bevacizumab plus 
chemotherapy continued beyond first progression in patients 
with metastatic colorectal cancer previously treated with 
bevacizumab plus chemotherapy: ML18147 study KRAS 
subgroup findings. Annals of oncology : official journal of 
the European Society for Medical Oncology / ESMO. 2013; 
24:2342-2349.
15. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van 
Cutsem E, von Moos R, Vieitez JM, Bouche O, Borg C, 
Steffens CC, Alonso-Orduna V, Schlichting C, Reyes-
Rivera I, Bendahmane B, Andre T, et al. Continuation of 
bevacizumab after first progression in metastatic colorectal 
cancer (ML18147): a randomised phase 3 trial. The lancet 
oncology. 2013; 14:29-37.
16. Grothey A. VEGF inhibition beyond tumour progression. 
The lancet oncology. 2013; 14(1):2-3.
17. Giantonio BJ. Targeted therapies: Goldie-Coldman and 
bevacizumab beyond disease progression. Nature reviews 
Clinical oncology. 2009; 6:311-312.
18. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent 
D, Hedrick E and Kozloff M. Bevacizumab beyond first 
progression is associated with prolonged overall survival 
in metastatic colorectal cancer: results from a large 
observational cohort study (BRiTE). Journal of clinical 
oncology : official journal of the American Society of 
Clinical Oncology. 2008; 26:5326-5334.
19. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P and 
Scherer SJ. Markers of response for the antiangiogenic 
agent bevacizumab. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology. 
2013; 31:1219-1230.
20. Eng C, Kindler HL and Schilsky RL. Oral fluoropyrimidine 
treatment of colorectal cancer. Clinical colorectal cancer. 
2001; 1:95-103.
21. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin 
DJ and Jain RK. Vascular normalization by vascular 
endothelial growth factor receptor 2 blockade induces a 
pressure gradient across the vasculature and improves drug 
penetration in tumors. Cancer research. 2004; 64:3731-
3736.
22. Jain RK. Normalization of tumor vasculature: an emerging 
concept in antiangiogenic therapy. Science. 2005; 307:58-
62.
23. Willett CG, Duda DG, di Tomaso E, Boucher Y, 
Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, 
Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong 
TZ, Paulson E, Poleski M, Vujaskovic Z, et al. Efficacy, 
safety, and biomarkers of neoadjuvant bevacizumab, 
radiation therapy, and fluorouracil in rectal cancer: a 
multidisciplinary phase II study. Journal of clinical 
oncology : official journal of the American Society of 
Clinical Oncology. 2009; 27:3020-3026.
24. Baar J, Silverman P, Lyons J, Fu P, Abdul-Karim F, Ziats N, 
Wasman J, Hartman P, Jesberger J, Dumadag L, Hohler E, 
Leeming R, Shenk R, Chen H, McCrae K, Dowlati A, et al. 
A vasculature-targeting regimen of preoperative docetaxel 
with or without bevacizumab for locally advanced breast 
cancer: impact on angiogenic biomarkers. Clinical cancer 
research : an official journal of the American Association 
for Cancer Research. 2009; 15:3583-3590.
25. Fan F, Samuel S, Gaur P, Lu J, Dallas NA, Xia L, Bose 
D, Ramachandran V and Ellis LM. Chronic exposure 
of colorectal cancer cells to bevacizumab promotes 
compensatory pathways that mediate tumour cell migration. 
British journal of cancer. 2011; 104:1270-1277.
26. Heid CA, Stevens J, Livak KJ and Williams PM. Real time 
quantitative PCR. Genome research. 1996; 6(10):986-994.
27. Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu 
D, Vallbohmer D, Park S, Danenberg KD, Takasaki K 
and Danenberg PV. Vascular endothelial growth factor 
messenger RNA expression level is preserved in liver 
metastases compared with corresponding primary colorectal 
cancer. Clinical cancer research : an official journal of the 
American Association for Cancer Research. 2006; 12:29-
33.
28. Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, 
Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen 
S, Hoelscher AH, Schneider PM and Danenberg PV. 
Downregulation of TS, DPYD, ERCC1, GST-Pi, EGFR, 
and HER2 gene expression after neoadjuvant three-modality 
treatment in patients with esophageal cancer. Journal of the 
American College of Surgeons. 2005; 200:336-344.
29. Livak KJ and Schmittgen TD. Analysis of relative gene 
expression data using real-time quantitative PCR and the 
2(-Delta Delta C(T)) Method. Methods. 2001; 25:402-408.
